Which monoclonal antibodies are used to target IL-1?

Which monoclonal antibodies are used to target IL-1?

• A. Anakinra, rilonacept, and canakinumab
• B. Adalimumab and infliximab
• C. Etanercept and ustekinumab
• D. Secukinumab and ixekizumab

Answer: (A)

The correct answer focuses on the monoclonal antibodies that specifically target interleukin-1 (IL-1), a key cytokine involved in inflammatory responses. Anakinra is a recombinant form of the human IL-1 receptor antagonist, which blocks the effects of IL-1 by preventing it from binding to its receptor, effectively reducing inflammatory activity. Rilonacept is a soluble receptor that binds to both IL-1α and IL-1β, thereby inhibiting their activity. Canakinumab is a monoclonal antibody specifically directed against IL-1β, directly neutralizing this cytokine and preventing it from exerting its pro-inflammatory effects. Thus, these three agents are focused on modulating the IL-1 pathway, making them effective in conditions characterized by IL-1 driven inflammation. In contrast, the other options listed include monoclonal antibodies that target different cytokines. For instance, adalimumab and infliximab target tumor necrosis factor alpha (TNF-α), while etanercept also acts on TNF-α. Ustekinumab targets interleukin-12 (IL-12) and interleukin-23 (IL-23). Secukinumab and ixek

The correct answer focuses on the monoclonal antibodies that specifically target interleukin-1 (IL-1), a key cytokine involved in inflammatory responses.

Anakinra is a recombinant form of the human IL-1 receptor antagonist, which blocks the effects of IL-1 by preventing it from binding to its receptor, effectively reducing inflammatory activity. Rilonacept is a soluble receptor that binds to both IL-1α and IL-1β, thereby inhibiting their activity. Canakinumab is a monoclonal antibody specifically directed against IL-1β, directly neutralizing this cytokine and preventing it from exerting its pro-inflammatory effects.

Thus, these three agents are focused on modulating the IL-1 pathway, making them effective in conditions characterized by IL-1 driven inflammation.

In contrast, the other options listed include monoclonal antibodies that target different cytokines. For instance, adalimumab and infliximab target tumor necrosis factor alpha (TNF-α), while etanercept also acts on TNF-α. Ustekinumab targets interleukin-12 (IL-12) and interleukin-23 (IL-23). Secukinumab and ixek